The FDA grants Fast Track designation to CDI-988, an oral antiviral for the treatment and prophylaxis of norovirus infection in adult patients.

COCP READ THE FULL COCP RESEARCH REPORT Business Update Fast Track Designation for CDI-988 On April 2, 2026, Cocrystal Pharma, Inc. (NASDAQ: COCP) announced that the U.S. Food and Drug Administration ...

CDI-988 was designed and developed as an inhibitor of a highly conserved region of noroviruses, coronaviruses, and other 3CL viral proteases. A Phase 1b norovirus challenge study is underway at Emory ...

FDA Fast Track designation supports accelerated development and expedites regulatory reviewNorovirus is responsible for an ...

Phase 1b norovirus challenge study is underway at Emory University School of MedicineCDI-988 is the first oral antiviral ...

The Mater Hospital in Dublin is advising people planning to attend the hospital today that staff are currently managing an ...

A doctor shared four warning signs of norovirus infection that you should be aware of for prompt treatment. Some of these ...

AI predicted that a forgotten breast cancer drug could be repurposed to treat many respiratory and gastrointestinal viruses, ...

Cocrystal stated that the Fast Track designation is aimed at facilitating the development of drugs that treat serious conditions and address unmet medical needs, while also accelerating their review ...

People are being urged to be aware of important information during the doctors strike ...

NOROVIRUS cases are continuing to soar across Ireland with figures now almost double stats from the last four years. The continued prevalence of the nasty vomiting bug has forced another Irish ...

A hospital has brought in visiting restrictions on its wards because of an increase in norovirus cases. Surrey & Sussex ...